Thrombolysis treatment for acute ischaemic stroke in a patient on treatment with dabigatran

María Consuelo Matute; Marta Guillán; Juan García-Caldentey; Javier Buisán; María Aparicio; Jaime Masjuan; María Alonso de Leciñana

doi:10.1160/TH11-01-0042

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2011; 106(01): 178-179
DOI: 10.1160/TH11-01-0042

Letters to the Editor

Schattauer GmbH

Thrombolysis treatment for acute ischaemic stroke in a patient on treatment with dabigatran

Authors

María Consuelo Matute

¹Department of Neurology, Stroke Unit, University Hospital Ramón y Cajal, IRYCIS, Madrid, Spain
Marta Guillán

¹Department of Neurology, Stroke Unit, University Hospital Ramón y Cajal, IRYCIS, Madrid, Spain
Juan García-Caldentey

¹Department of Neurology, Stroke Unit, University Hospital Ramón y Cajal, IRYCIS, Madrid, Spain
Javier Buisán

¹Department of Neurology, Stroke Unit, University Hospital Ramón y Cajal, IRYCIS, Madrid, Spain
María Aparicio

¹Department of Neurology, Stroke Unit, University Hospital Ramón y Cajal, IRYCIS, Madrid, Spain
Jaime Masjuan

¹Department of Neurology, Stroke Unit, University Hospital Ramón y Cajal, IRYCIS, Madrid, Spain
María Alonso de Leciñana

¹Department of Neurology, Stroke Unit, University Hospital Ramón y Cajal, IRYCIS, Madrid, Spain

Abstract

Full Text

References

References
1 Adams HP, Jr del Zoppo G, Alberts MJ. et al American Heart Association; American Stroke Association Stroke Council; Clinical Cardiology Council; Cardiovascular Radiology and Intervention Council; Athero sclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups. Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/ American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: the American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Stroke 2007; 38: 1655-1711.
2 Connolly SJ, Ezekowitz MD, Yusuf S. et al. RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fribrillation. N Engl J Med 2009; 361: 1139-1151.
3 Dempfle CE, Hennerici MG. Dabigatran and stroke thrombolysis. Cerebrovasc Dis 2010; 30: 203-205.
4 van Ryn J, Stangier J, Haertter S. et al. Dabigatran et- exilate - a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010; 103: 1116-1127.
5 Lindahl TL, Baghaei F, Fagerberg Blixter I. et al. and from the expert group on coagulation of the External Quality Assurance in Laboratory Medicine in Sweden. Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays. Thromb Haemost 2011; 105: 371-378.
6 Boehringer Ingelheim Canada. Pradrax™ Product Monograph, rev.. Burlington: Boehringer Ingelheim Canada; 2009
7 De Smedt A, De Raedt S, Nieboer K. et al. Intravenous Thrombolysis with Recombinant Tissue Plasminogen Activator in a Stroke Patient Treated with Dabigatran. Cerebrovasc Dis 2010; 30: 533-534.